Eli Lilly (LLY)
1,061.47
+19.82 (1.90%)
NYSE· Last Trade: May 22nd, 1:25 PM EDT
Detailed Quote
| Previous Close | 1,041.65 |
|---|---|
| Open | 1,049.81 |
| Bid | 1,061.25 |
| Ask | 1,062.16 |
| Day's Range | 1,047.07 - 1,069.11 |
| 52 Week Range | 623.78 - 1,133.95 |
| Volume | 1,609,544 |
| Market Cap | 1.02T |
| PE Ratio (TTM) | 46.25 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.65%) |
| 1 Month Average Volume | 3,425,492 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts
Via Talk Markets · May 22, 2026
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
Via StockStory · May 22, 2026
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
Via Benzinga · May 21, 2026
Demand for weight loss drugs may fuel growth for more than one player.
Via The Motley Fool · May 21, 2026
Eli Lilly & Co (NYSE:LLY) Proves a Smart Pick for a Rules-Based Dividend Growth Strategychartmill.com
Via Chartmill · May 21, 2026
LLY: Eli Lilly & Co. Passes the Affordable Growth (GARP) Screen with Strong Momentum and Fair Valuationchartmill.com
Via Chartmill · May 18, 2026
Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.
Via Investor's Business Daily · May 21, 2026
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END
Via FinancialNewsMedia · May 21, 2026
Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products
By MarketNewsUpdates.com · Via GlobeNewswire · May 21, 2026
It's tough to think of an industry with more staying power than healthcare.
Via The Motley Fool · May 21, 2026
If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.
Via The Motley Fool · May 20, 2026
Looking back on pharmaceuticals stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Elanco (NYSE:ELAN) and its peers. The pha...
Via StockStory · May 20, 2026
Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.
Via MarketBeat · May 20, 2026
Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.
Via Benzinga · May 19, 2026
This dark horse in the weight loss drug race is worth keeping on your watch list.
Via The Motley Fool · May 18, 2026
The company is riding an incredible tailwind.
Via The Motley Fool · May 18, 2026
Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.
Via Benzinga · May 18, 2026
These stocks could look like steals in a few years.
Via The Motley Fool · May 18, 2026
Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
Via The Motley Fool · May 17, 2026
There's a new challenger to the more established players in the weight-loss drug space.
Via The Motley Fool · May 16, 2026
Via Benzinga · May 15, 2026
Can Novo Nordisk thrive under intense competitive pressures?
Via The Motley Fool · May 15, 2026
Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.
Via The Motley Fool · May 15, 2026
The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.
Via Barchart.com · May 14, 2026
Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.
Via The Motley Fool · May 14, 2026
